These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28058221)

  • 1. Quality of life 10 years after liver transplantation: The impact of graft histology.
    Karam V; Sebagh M; Rifai K; Yilmaz F; Bhangui P; Danet C; Saliba F; Samuel D; Castaing D; Adam R; Feray C
    World J Transplant; 2016 Dec; 6(4):703-711. PubMed ID: 28058221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C.
    Wali M; Harrison RF; Gow PJ; Mutimer D
    Gut; 2002 Aug; 51(2):248-52. PubMed ID: 12117889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Old donors in liver transplantation for chronic hepatitis C].
    Aguilera V; Ponce M; Berenguer M; Moreno R; Rayón JM; Sanjuán F; Prieto M; Mir J
    Rev Esp Enferm Dig; 2007 Oct; 99(10):581-7. PubMed ID: 18052661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation.
    Machicao VI; Krishna M; Bonatti H; Aqel BA; Nguyen JH; Weigand SD; Rosser BG; Hughes C; Dickson RC
    Liver Transpl; 2004 May; 10(5):599-606. PubMed ID: 15108251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis.
    Briceño J; Ciria R; Pleguezuelo M; de la Mata M; Muntané J; Naranjo A; Sánchez-Hidalgo J; Marchal T; Rufián S; López-Cillero P
    Liver Transpl; 2009 Jan; 15(1):37-48. PubMed ID: 19109846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection.
    Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Cabrera R; Shuster JJ; Theriaque D; Reed AI; Hemming AW; Liu C; Crawford JM; Nelson DR
    Liver Transpl; 2004 Oct; 10(10):1240-7. PubMed ID: 15376304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.
    Lim KB; Sima HR; Fiel MI; Khaitova V; Doucette JT; Chernyiak M; Ahmad J; Bach N; Chang C; Grewal P; Kim-Schluger L; Liu L; Odin J; Perumalswami P; Florman SS; Schiano TD
    World J Gastroenterol; 2015 May; 21(20):6236-45. PubMed ID: 26034358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
    Pembroke T; Deschenes M; Lebouché B; Benmassaoud A; Sewitch M; Ghali P; Wong P; Halme A; Vuille-Lessard E; Pexos C; Klein MB; Sebastiani G
    J Hepatol; 2017 Oct; 67(4):801-808. PubMed ID: 28527666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C.
    Jain A; Kashyap R; Demetris AJ; Eghstesad B; Pokharna R; Fung JJ
    Liver Transpl; 2002 Jan; 8(1):40-6. PubMed ID: 11799484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor age influences 10-year liver graft histology independently of hepatitis C virus infection.
    Rifai K; Sebagh M; Karam V; Saliba F; Azoulay D; Adam R; Castaing D; Bismuth H; Reynès M; Samuel D; Féray C
    J Hepatol; 2004 Sep; 41(3):446-53. PubMed ID: 15336448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver transplant recipients and prioritization of anti-HCV therapy: an Italian cohort analysis.
    Lanini S; Nanni Costa A; Grossi PA; Procaccio F; Ricci A; Capobianchi MR; Terrault NA; Ippolito G
    Liver Int; 2016 Mar; 36(3):410-7. PubMed ID: 26264452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo hepatic steatosis drives atherogenic risk in liver transplantation recipients.
    Idowu MO; Chhatrala R; Siddiqui MB; Driscoll C; Stravitz RT; Sanyal AJ; Bhati C; Sargeant C; Luketic VA; Sterling RK; Contos M; Matherly S; Puri P; Siddiqui MS
    Liver Transpl; 2015 Nov; 21(11):1395-402. PubMed ID: 26228654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: model to predict HCV cirrhosis after liver transplantation.
    Iacob S; Cicinnati VR; Hilgard P; Iacob RA; Gheorghe LS; Popescu I; Frilling A; Malago M; Gerken G; Broelsch CE; Beckebaum S
    Transplantation; 2007 Jul; 84(1):56-63. PubMed ID: 17627238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C.
    Burak KW; Kremers WK; Batts KP; Wiesner RH; Rosen CB; Razonable RR; Paya CV; Charlton MR
    Liver Transpl; 2002 Apr; 8(4):362-9. PubMed ID: 11965581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal prospective study on quality of life and psychological distress before and one year after liver transplantation.
    Burra P; De Bona M; Canova D; Feltrin A; Ponton A; Ermani M; Brolese A; Rupolo G; Naccarato R
    Acta Gastroenterol Belg; 2005; 68(1):19-25. PubMed ID: 15832583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transforming growth factor β1 polymorphisms and progression of graft fibrosis after liver transplantation for hepatitis C virus--induced liver disease.
    Eurich D; Bahra M; Boas-Knoop S; Lock JF; Golembus J; Neuhaus R; Neuhaus P; Neumann UP
    Liver Transpl; 2011 Mar; 17(3):279-88. PubMed ID: 21384510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor Factors Including Donor Risk Index Predict Fibrosis Progression, Allograft Loss, and Patient Survival following Liver Transplantation for Hepatitis C Virus.
    Jesudian A; Desale S; Julia J; Landry E; Maxwell C; Kallakury B; Laurin J; Shetty K
    J Clin Exp Hepatol; 2016 Jun; 6(2):109-14. PubMed ID: 27493458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection.
    Berres ML; Trautwein C; Schmeding M; Eurich D; Tacke F; Bahra M; Neuhaus P; Neumann UP; Wasmuth HE
    Hepatology; 2011 Feb; 53(2):596-603. PubMed ID: 21274880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negativization of viremia prior to liver transplant reduces early allograft dysfunction in hepatitis C-positive recipients.
    Martini S; Tandoi F; Terzi di Bergamo L; Strona S; Lavezzo B; Sacco M; Maione F; Gonella F; Strignano P; Dell Olio D; Salizzoni M; Saracco GM; Romagnoli R
    Liver Transpl; 2017 Jul; 23(7):915-924. PubMed ID: 28422425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation.
    Kim H; Lee K; Lee KW; Yi NJ; Lee HW; Hong G; Choi Y; You T; Suh SW; Jang JJ; Suh KS
    Clin Transplant; 2014 May; 28(5):521-9. PubMed ID: 24579874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.